GSK (LSE:GSK) Could Be 14% Below Fair Value As R and D Spending Rises

GSK (LSE:GSK) has drawn attention after committing more than US$800m to expand its Pennsylvania biopharmaceutical campus, while at the same time cutting over 1,800 jobs in Europe and deepening its AI driven research partnership with Chai Discovery.

Recent trading shows that GSK shares have gained 2.89% on a 1 day basis and 7.66% over the past week. The 1 year total shareholder return of 18.42% and 5 year total shareholder return of 60.75% point to momentum that has built over time around its R&D heavy pipeline moves, restructuring programme and fresh capital access through the new US$3.05b shelf registration for American Depositary Shares tied to employee plans.

Capitalize on GSK's refocus on high value R&D by scanning a hand picked set of resilient healthcare stocks with 4 resilient stocks with low risk scores.

Bulls see GSK’s US$800m expansion and AI partnership as a springboard for its pipeline, while bears focus on restructuring risk and mature franchises. Which story does the current valuation reflect?

Most Popular Narrative: 14% Undervalued

GSK last closed at £18.69, while the most widely followed narrative pegs fair value at £21.73 using a 7.56% discount rate. That gap frames the whole debate around whether the R&D heavy plan and cost savings programme are being fully recognised.

The oncology portfolio is scaling through business development backed precision and antibody drug conjugate assets, including the Nuvalent programs and broad Phase III plans for agents such as Mo rez and Ris rez across lung, gynecologic, prostate, GIST and myeloma indications. This can expand future specialty medicines revenue and improve mix driven margins.

See why 214 investors see GSK as 14% undervalued.

Result: Fair Value of £21.73 (UNDERVALUED)

Still, the story around GSK can change quickly if loss of exclusivity in key HIV products bites harder than expected or if further late stage R&D setbacks emerge.

Find out about the key risks to this GSK narrative.

Next Steps

Mixed signals around GSK can be useful if you are willing to check the underlying data yourself and decide what matters most for you. To weigh both the potential upsides and the issues flagged by other investors, start by looking at the 4 key rewards and 3 important warning signs.

Ready for more investment ideas beyond GSK?

Do not stop at one opportunity when a broader watchlist can help you spot patterns, pressure test your thinking and uncover ideas GSK alone cannot show you.

• Target resilient potential compounders by scanning companies that look undervalued on quality and fundamentals through the 9 high quality undervalued stocks.
• Strengthen your downside protection by focusing on businesses with cash and debt profiles that can absorb shocks using the list of solid balance sheet and fundamentals (9 results).
• Hunt for less crowded opportunities by filtering for strong fundamentals that the market has not widely focused on yet via the 5 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com